Product Description
Mechanisms of Action: TLR2 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Opsona
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Heart Transplant|Kidney Transplant|Renal Transplant|Heart Block|Inflammation|Preleukemia|Myelodysplastic Syndrome|Transplantation Unspecified
Phase 1: Parkinson's Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05790382 |
NM-101-01-2022 | P1 |
Unknown status |
Parkinson's Disease |
2024-05-30 |
11% |
2025-03-04 |
Primary Endpoints|Treatments|Trial Status |
NCT03337451 |
OPN-305-110 | P2 |
Completed |
Preleukemia|Myelodysplastic Syndrome |
2019-01-10 |
33% |
2019-03-21 |
Primary Completion Date |
NCT02363491 |
OPN-305-106 | P2 |
Completed |
Myelodysplastic Syndrome|Preleukemia |
2018-12-01 |
23% |
2019-03-20 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
NCT01794663 |
OPN305-102 | P2 |
Completed |
Kidney Transplant|Renal Transplant|Inflammation|Heart Block|Heart Transplant |
2016-06-30 |
2019-03-19 |
Treatments |
|
2012-001455-39 |
2012-001455-39 | P2 |
Completed |
Renal Transplant|Kidney Transplant |
2016-06-30 |
2022-03-13 |
Treatments |
|
2012-005767-27 |
2012-005767-27 | P2 |
Completed |
Renal Transplant|Transplantation Unspecified |
2016-06-06 |
2022-03-13 |
Treatments |
|
2012-005768-90 |
2012-005768-90 | P2 |
Completed |
Renal Transplant |
2014-02-14 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/10/2022 |
News Article |
Bioasis and Neuramedy Enter into Research Collaboration and License Agreement |